Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Corporate
      September 13, 2017

      Johnson & Johnson Launches Dr. Paul Janssen Project to Catalyze and Convene Champions of Science Across Generations and Geographies

      Shark Tank’s Daymond John to Judge the First Champions of Science “What’s New?” Challenge Multifaceted Platform to Broaden Public Engagement in Science
      Learn more
      Innovative Medicine
      September 6, 2017

      ACTELION RECEIVES FDA APPROVAL OF TRACLEER® (bosentan) FOR USE IN PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

      --First PAH medication approved in the U.S. for pediatric patients aged three years and older--
      Learn more
      Innovative Medicine
      September 5, 2017

      Idylla™ Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

      Learn more
      Innovative Medicine
      August 27, 2017

      XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study

      Learn more
      Innovative Medicine
      August 21, 2017

      New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Includes Late-Breaking Results from Landmark Phase 3 COMPASS Study

      Learn more
      Innovative Medicine
      August 16, 2017

      Johnson & Johnson Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments

      Memorandum of Understanding brings together best scientists from India and Johnson & Johnson to increase and accelerate pace of innovation needed to make TB history
      Learn more
      Innovative Medicine
      August 2, 2017

      U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy

      Learn more
      Innovative Medicine
      July 27, 2017

      Janssen Enters Collaboration with Bavarian Nordic to Develop Vaccines Against Hepatitis B Virus and HIV-1

      Collaboration to combine Janssen’s vaccine technologies with MVA-BN® technology from Bavarian Nordic to advance potential new vaccine regimens
      Learn more
      Innovative Medicine
      July 24, 2017

      Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen

      Learn more
      Load more